Overview

Anti-RSV Study in Chinese Patients (ASCENT)

Status:
Unknown status

Trial end date:
2020-06-30

Target enrollment:

Participant gender:

Summary

This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered AK0529 in Chinese adults with RSV infection.

Phase:

Phase 2

Details

Lead Sponsor:

Ark Biosciences Inc.

Treatments:

Ziresovir